Their differentiation, guided by factors like erythropoietin (EPO) and granulocyte colony stimulating factor (G-CSF), underscores their potential in treating blood-related pathologies associated with AIS [387,388]. This evidence concerns the gene CSF3 and androgen insensitivity syndrome.